20 November 2019

NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda

The meeting will start promptly at 09:30 and is expected to finish at approximately 17:15

Please note that this agenda is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Appraisal of Entrectinib for treating NTRK fusion-positive solid tumours [ID1512]

    The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for Entrectinib for treating ROS1 fusion-positive locally advanced or metastatic non-small-cell lung cancer and as a consequence this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).

          5.1. Declarations of interest – Part 2 only (closed session)
    • 5.2. Introduction by the Chair, Professor Gary McVeigh– Part 2 only (closed session)
    • 5.3. Presentation by the lead team, Guy Makin, Peter Hall and Malcolm Oswald– Part 2 only (closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of Larotrectinib for treating NTRK fusion-positive advanced solid tumours [ID1299]
          6.1. Declarations of interest - Part 1 only (open session)
          6.2. Introduction by the Chair, Professor Gary McVeigh– Part 1 only (open session)
          6.3.  Presentation by the lead team, Guy Makin, David Meads and Malcolm Oswald - Part 1 AND part 2 (open and closed session)
          6.4.  Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Entrectinib for treating ROS1 fusion-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

    The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for Entrectinib for treating ROS1 fusion-positive locally advanced or metastatic non-small-cell lung cancer and as a consequence this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).

          7.1. Declarations of interest - Part 2 only (closed session)
          7.2. Introduction by the Chair, Professor Gary McVeigh– Part 2 only (closed session)
          7.3.  Presentation by the lead team, Matt Bradley, Soo Fon Lim and Rebecca Harmston- Part 2 only (closed session)
          7.4.  Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Tuesday 7 January 2020 at 10:00, at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Wednesday 6 November 2019Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Sandra Robinson.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 23 October 2019 to 06 November 2019
Registration is closed.